HURA Projected Dividend Yield

Tuhura Biosciences Inc ( NASDAQ : HURA )

Kintara Therapeutics, Inc. is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. Co.'s lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. It has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product.

20 YEAR PERFORMANCE RESULTS